EUCTR2007-002931-95-BE进行中(未招募)1 期
The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size. - NOMI
Z Leuven0 个研究点目标入组 230 人开始时间: 2007年11月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The patient must meet the following criteria:
- •1. Acute myocardial infarction (defined as an episode of chest pain or related symptom lasting greater than 2 hours but less than 12 hours and electrocardiographic evidence of ST elevation (measured as 0.08 seconds after the J point; sum >= 0.6 mV in leads I, II, III, AVL, AVF, V1-V6).
- •2. No evidence of congestive heart failure (no S3 or evidence of pulmonary edema) and normal oxygen saturation on = 2L oxygen by NC.
- •3. Age > 18 years.
- •4. Signed EC approved informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 92
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 138
排除标准
- •The patient will be excluded from enrollment if any of the following are true:
- •1. Prior myocardial infarction (as determined by patient history and/or ECG), cardiac surgery, or severe pericardial, congenital, cardiomyopathic or valvular heart disease.
- •2. Requirement for urgent cardiac surgery.
- •3. Previous CABG or PCI.
- •4. Left bundle branch block.
- •5. Unable to tolerate magnetic resonance imaging (including disallowed metallic implants or BMI > 35) or unable to tolerate gadolinium contrast media, including patients with calculated creatinine clearance less than 60 ml/min/1.73 m2 BSA.
- •6. Active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation or hemorrhagic stroke within the 6 weeks prior to presentation.
- •7. Known or suspected aortic dissection.
- •8. Prior history of pulmonary disease requiring chronic oxygen therapy.
- •9. Pregnancy, lactating and woman of childbearing potential.
- •10. Use of investigational drugs or device within the 30 days prior to enrollment to the study. Investigational uses of approved therapies will be allowed.
- •11. Medical problem likely to preclude completion of the study.
研究者
相似试验
进行中(未招募)
不适用
The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size. - NOMIMyocardial InfarctionEUCTR2007-002931-95-DEINO Therapeutics200
进行中(未招募)
不适用
The effects of Nitric Oxide for Inhalation on MYocardial Infarction SizeMedDRA version: 14.0Level: PTClassification code 10028596Term: Myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersMyocardial InfarctionEUCTR2007-002931-95-HUZ Leuven200
已完成
2 期
Effects of Nitric Oxide for Inhalation in Myocardial Infarction SizeAcute Myocardial InfarctionNCT01398384Universitaire Ziekenhuizen KU Leuven250
进行中(未招募)
不适用
The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD)Implantation. - INOT41acute right ventricular failureMedDRA version: 9.1Level: LLTClassification code 10063082Term: Acute right ventricular failureEUCTR2005-000326-24-DEINO Therapeutics110
进行中(未招募)
1 期
The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD) Implantation. - INOT41EUCTR2005-000326-24-GBINO Therapeutics110
